Lumateperone is a new drug recently approved by the FDA for treatment of schizophrenia. The key clinical trial was just published and includes data on motor side effects of the drug. The sponsor, Intra-Cellular Therapies, Inc., may have data on use in Parkinson disease (PD), but I don’t think any of it is public. So […]
This article about an important detail in treating hallucinations or delusions in Parkinson disease patients was just published. Read all about it here.
This web page describes our work, just published, that maps movement-related and non-movement-related effects of deep brain stimulation in Parkinson disease patients.
A recent article from CNN discussed Nuplazid® (pimavanserin), a medication approved by the FDA in 2016 for treatment of hallucinations or delusions in Parkinson’s disease (a.k.a. PDP, for Parkinson disease psychosis). The article made some efforts to present a balanced perspective, but the title and overall tenor of the article focused on the possibility that this new […]